amgen maritide - Search News

News

Amgen, weight loss

Amgen gears up for phase 3 trial of monthly weight-loss drug MariTide amid mixed investor sentiment

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its phase 3 trial.

Barron's on MSN · 1d

Amgen Shares Fall on Weight-Loss Drug Tummy Troubles

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that lots of patients had stopped taking Amgen’s experimental weight loss shot after experiencing gastrointestinal distress.

Reuters on MSN · 1d

Amgen experimental weight-loss drug needs lower dose to limit side effects

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like vomiting, according to mid-stage trial results presented at a medical meeting on Monday that pushed the company's shares down nearly 6%.

Fierce Biotech1d

Amgen rolls out phase 3 dosing plan for lead obesity candidate after midstage trial sees high discontinuation, vomiting rates

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

1d

Ozempic and Mounjaro have new competitor as trial sees people lose 20% of body weight in one year

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

1d

What’s Happening With Amgen Stock?

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Amgen announces phase 2 obesity study results of MariTide; presents at 85th American Diabetes Association Scientific Sessions

Thousand Oaks, California Wednesday, June 25, 2025, 13:00 Hrs [IST] ...

1d

Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

BioPharma Dive1d

New Amgen obesity drug data disappoint Wall Street

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results